Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
Description: Enanta Pharmaceuticals, Inc., a biotechnology company, is engaged in the development of small molecule drugs for the infectious disease field. Its product portfolio includes ABT-450, a protease inhibitor that is in Phase III clinical trials for the treatment of hepatitis C virus (HCV); ABT-493, a next-generation protease inhibitor for HCV infection; EDP-239, an NS5A inhibitor for HCV infection; Cyclophilin inhibitor, which are in preclinical development stage for HCV infection treatment; and Nucleotide Polymerase inhibitor program for HCV infection. The company also develops Bicyclolide antibiotic products comprising EDP-788 for the treatment of methicillin-resistant Staphylococcus aureus bacteria. It has collaboration and license agreements with Novartis Institutes for BioMedical Research, Inc.; and AbbVie Inc. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||36.42%||Sales Growth - Q/Q||-25.98%||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||47.08%||ROE||51.63%||ROI|
|Current Ratio||8.98||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.09|
|Gross Margin||Operating Margin||82.62%||Net Profit Margin||64.48%||Dividend Payout Ratio|
|Cash From Financing Activities||2.26 M||Cash From Investing Activities||-100.46 M||Cash From Operating Activities||93.25 M||Gross Profit|
|Net Profit||28.75 M||Operating Profit||48.56 M||Total Assets||245.88 M||Total Current Assets||177.78 M|
|Total Current Liabilities||19.79 M||Total Debt||180 K||Total Liabilities||21.67 M||Total Revenue||57.37 M|
|High 52 week||105.66||Low 52 week||57.95||Last close||59.48||Last change||2.09%|
|RSI||24.08||Average true range||3.15||Beta||1.05||Volume||182.38 K|
|Simple moving average 20 days||-6.19%||Simple moving average 50 days||-11.99%||Simple moving average 200 days||-28.44%|
|Performance Week||2.41%||Performance Month||-14.89%||Performance Quart||-27.21%||Performance Half||-35.06%|
|Performance Year||-20.36%||Performance Year-to-date||-16.02%||Volatility daily||3.86%||Volatility weekly||8.64%|
|Volatility monthly||17.71%||Volatility yearly||61.35%||Relative Volume||295.56%||Average Volume||208.95 K|
|New High||0.99%||New Low|
2020-05-14 08:53:12 | Why Enanta Pharmaceuticals ENTA Stock Might be a Great Pick
2020-05-09 21:43:21 | Were Hedge Funds Right About Enanta Pharmaceuticals Inc ENTA?
2020-05-07 01:37:58 | Edited Transcript of ENTA earnings conference call or presentation 6-May-20 8:30pm GMT
2020-05-07 00:01:27 | Enanta Pharmaceuticals Inc ENTA Q2 2020 Earnings Call Transcript
2020-05-06 18:45:10 | Enanta Pharmaceuticals ENTA Reports Q2 Loss, Misses Revenue Estimates
2020-04-17 10:19:16 | Is Enanta Pharmaceuticals NASDAQ:ENTA Using Too Much Debt?
2020-03-26 16:05:00 | Enanta Provides Update on Clinical Development Activities During COVID-19 Pandemic
2020-03-06 07:05:00 | Enanta’s HCV Collaboration Partner AbbVie Receives Marketing Authorization from European Commission to Shorten MAVIRET® glecaprevir/pibrentasvir Duration to Eight Weeks for Treatment-Naïve Genotype 3 HCV Patients with Compensated Cirrhosis
2020-03-04 08:09:24 | Does Market Volatility Impact Enanta Pharmaceuticals, Inc.'s NASDAQ:ENTA Share Price?
2020-02-10 18:29:44 | Edited Transcript of ENTA earnings conference call or presentation 6-Feb-20 9:30pm GMT
2020-02-06 17:15:10 | Enanta Pharmaceuticals ENTA Q1 Earnings Top Estimates
2020-02-06 14:30:00 | Enanta Pharmaceuticals, Inc. to Host Earnings Call
2020-02-05 16:11:53 | 13 Key NASH Drug Candidates To Watch For In A Potential $30-Billion Market
2020-02-03 07:27:17 | Is Enanta Pharmaceuticals, Inc.'s NASDAQ:ENTA High P/E Ratio A Problem For Investors?
2020-01-30 12:31:05 | Earnings Preview: Enanta Pharmaceuticals ENTA Q1 Earnings Expected to Decline
2020-01-14 05:30:00 | AbbVie's MAVIRET® now listed on the Newfoundland and Labrador formulary
2019-12-30 07:30:00 | Enanta Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference
2019-12-11 11:25:24 | Is Enanta Pharmaceuticals Inc ENTA A Good Stock To Buy?
2019-12-09 07:38:17 | Should You Worry About Enanta Pharmaceuticals, Inc.'s NASDAQ:ENTA CEO Pay Cheque?
2019-11-27 00:09:34 | Edited Transcript of ENTA earnings conference call or presentation 21-Nov-19 9:30pm GMT
2019-11-21 17:15:10 | Enanta Pharmaceuticals ENTA Lags Q4 Earnings and Revenue Estimates
2019-11-17 08:42:54 | The Week Ahead In Biotech: Clinical Readouts In Focus As Earnings Wind Down
2019-11-11 10:21:50 | Is Enanta Pharmaceuticals, Inc.'s NASDAQ:ENTA 14% ROE Worse Than Average?
2019-11-11 07:30:00 | Enanta Pharmaceuticals Announces Poster Presentations at The Liver Meeting® 2019
2019-10-27 22:29:08 | Enanta Pharmaceuticals Inc ENTA: Hedge Funds In Wait-and-See Mode
2019-10-21 16:00:00 | Enanta Pharmaceuticals to Present at the 2019 Wolfe Research Healthcare Conference
2019-10-12 10:03:32 | Is Enanta Pharmaceuticals's NASDAQ:ENTA Share Price Gain Of 145% Well Earned?
2019-10-03 07:30:00 | New Data from Enanta’s Phase 2a Human Challenge Study of EDP-938 for RSV Demonstrates Highly Statistically Significant Reductions p<0.001 in Total Symptom Score, Mucus Weight and RSV Viral Load as Measured by RT-PCR Assay and by Plaque Assay
2019-09-29 15:01:41 | The Week Ahead In Biotech Sept. 29-Oct. 5: Conference Presentations, IPOs Hit Top Gear
2019-09-26 16:16:41 | This Biotech Stock Just Careened Toward Its Lowest Point In Nearly 2 Years
2019-09-26 11:40:03 | Enanta's Stock Down Despite NASH Drug Meeting Goal in Study